Hongkongers to pay only HK$240 a year for leukaemia drug after system shake-up

“More than 400 cancer patients are set to benefit from Hong Kong health authorities’ decision to subsidise a leukaemia drug, and will go from paying up to HK$500,000 (US$63,800) a year for treatment to forking out just HK$240. The Hospital Authority said on Wednesday that it began subsidising the medication, Dasatinib, in April, with the government expected to set aside an additional HK$49 million in annual spending to help cover the cost. As part of the move, Dasatinib was reclassified from a...

Summary generated from the RSS feed of SCMP Hong Kong. All article rights belong to the original publisher. Click through to read the full piece on www.scmp.com/news/hong-kong.